近日，中国生物科技公司依生生物宣布将与特殊目的收购公司 Summit Healthcare Acquisition Corp.完成合并。交易完成后，依生生物将更名为YS Biopharma并在纳斯达克实现上市。据协议，合并交易将募资最多2.3亿美元。
竞天公诚律师事务所、美国威尔逊•桑西尼•古奇•罗沙迪律师事务所、迈普达香港为依生生物提供法律服务；科律律师事务所、奥杰律师事务所则担任Summit的法律顾问。
依生生物成立于2002年，总部位于北京，在中国、美国、新加坡拥有共900多名员工。它是一家针对传染病以及癌症，发现、开发、制造及商业化新一代疫苗及治疗性生物制品的创新生物医药公司。本次合并交易的募集资金将主要用于皮卡狂犬疫苗及重组新冠疫苗在多国市场的临床试验和商业化。
威尔逊团队项目牵头人为合伙人欧阳丹律师。
Wilson, Cooley, Jingtian on biotech company’s $230 mln SPAC merger
YishengBio Co., Ltd, a commercialization-stage biopharmaceutical company focusing on innovative vaccines and therapeutic biologics, and Summit Healthcare Acquisition Corp., a publicly traded special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination. Upon the completion of the merger, the combined company will be renamed as YS Biopharma Co., Ltd. and become a publicly traded company on the Nasdaq.
Wilson Sonsini Goodrich & Rosati, Jingtian & Gongcheng and Maples and Calder (Hong Kong) are serving as legal advisors to YS Biopharma. Meanwhile, Cooley and Ogier are serving as legal advisors to Summit.
The merger is targeted to close in the first quarter of 2023. It is expected to provide up to approximately $230 million in gross proceeds, which will be used for the clinical development and future commercialization of the company’s rabies vaccine and recombinant COVID-19 vaccine in multiple countries.
The Wilson Sonsini team was led by partner Dan Ouyang.
